Transarterial Chemoembolization for Primary Hepatocellular Carcinoma in Patients at High Risk

Journal of Vascular and Interventional Radiology

Volumn 18, Issue 12, 2007, Pages 1517-1526

  Kothary, Nishita ^a   Weintraub, Joshua L ^b   Susman, Jonathan ^c   Rundback, John H ^d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d Holy Name Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CISPLATIN; DOXORUBICIN; MITOMYCIN C; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CANCER PATIENT; CHEMOEMBOLIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PORTAL VEIN; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36348969465     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2007.07.035     Document Type: Article

References (71)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. World Health Organization. Mortality Database. WHO. 2000. Available at: http://www.whoint/healthinfo/morttables/en/. Accessed October 20, 2006.
4. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
5. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
6. Hassan M.M., Frome A., Patt Y.Z., and El-Serag H.B. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 35 (2002) 266-269
7. Llovet J.M., Fuster J., and Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10 suppl (2004) S115-S120
8. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
9. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
10. Bruix J., and Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35 (2002) 519-524
11. Bismuth H., and Majno P.E. Hepatobiliary surgery. J Hepatol 32 (2000) 208-224
12. Llovet J.M., Mas X., Aponte J.J., et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50 (2002) 123-128
13. Yao F.Y., Bass N.M., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8 (2002) 873-883
14. Majno P.E., Adam R., Bismuth H., et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226 (1997) 688-701
15. Graziadei I.W., Sandmueller H., Waldenberger P., et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9 (2003) 557-563
16. Harnois D.M., Steers J., Andrews J.C., et al. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg 5 (1999) 192-199
17. Roayaie S., Frischer J.S., Emre S.H., et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235 (2002) 533-539
18. Hayashi P.H., Ludkowski M., Forman L.M., et al. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 4 (2004) 782-787
19. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
20. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
21. Camma C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
22. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
23. Chung J.W., Park J.H., Han J.K., et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198 (1996) 33-40
24. Savastano S., Miotto D., Casarrubea G., Teso S., Chiesura-Corona M., and Feltrin G.P. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 28 (1999) 334-340
25. Llado L., Virgili J., Figueras J., et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88 (2000) 50-57
26. Mondazzi L., Bottelli R., Brambilla G., et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 19 (1994) 1115-1123
27. Ahn S.H., Han K.H., Park J.Y., et al. Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa). Yonsei Med J 45 (2004) 847-858
28. Ueno K., Miyazono N., Inoue H., Nishida H., Kanetsuki I., and Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 88 (2000) 1574-1581
29. Shijo H., Okazaki M., Higashihara H., Koganemaru F., and Okumura M. Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization. Am J Gastroenterol 87 (1992) 1154-1159
30. Khan K.N., Nakata K., Kusumoto Y., et al. Evaluation of nontumorous tissue damage by transcatheter arterial embolization for hepatocellular carcinoma. Cancer Res 51 (1991) 5667-5671
31. Miyoshi S., Minami Y., Kawata S., et al. Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma: assessment by maximal removal rate of indocyanine green. J Hepatol 6 (1988) 332-336
32. MELD scores. UNOS Resource policy 3.6. Available at http://www.unos.org/resources/MeldPeldCalculator.asp?index=98. Accessed October 20, 2006.
33. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
34. Figueras J., Jaurrieta E., Valls C., et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 25 (1997) 1485-1489
35. Bismuth H., Majno P.E., and Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 19 (1999) 311-322
36. Keeffe E.B. Summary of guidelines on organ allocation and patient listing for liver transplantation. Liver Transpl Surg 4 suppl (1998) S108-S114
37. Wong L.L., Tanaka K., Lau L., and Komura S. Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 18 (2004) 227-234
38. Kamel I.R., Bluemke D.A., Ramsey D., et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181 (2003) 708-710
39. Berger D.H., Carrasco C.H., Hohn D.C., and Curley S.A. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 60 (1995) 116-121
40. Farinati F., De Maria N., Marafin C., et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 41 (1996) 2332-2339
41. Chung J.W. Transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatogastroenterology 45 suppl 3 (1998) 1236-1241
42. Sakamoto I., Aso N., Nagaoki K., et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 18 (1998) 605-619
43. Katsushima S., Inokuma T., Oi H., et al. Acute hepatic failure following transcatheter arterial embolization for the treatment of hepatocellular carcinoma. Digestion 58 (1997) 189-195
44. Kiely J.M., Rilling W.S., Touzios J.G., et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 17 (2006) 47-53
45. Chan A.O., Yuen M.F., Hui C.K., Tso W.K., and Lai C.L. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94 (2002) 1747-1752
46. Huang Y.S., Chiang J.H., Wu J.C., Chang F.Y., and Lee S.D. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 97 (2002) 1223-1227
47. Bronowicki J.P., Vetter D., Dumas F., et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 74 (1994) 16-24
48. Venook A.P., Stagg R.J., Lewis B.J., et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8 (1990) 1108-1114
49. Bruix J., Castells A., Montanya X., et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 20 (1994) 643-650
50. Bismuth H., Morino M., Sherlock D., et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 163 (1992) 387-394
51. Paye F., Farges O., Dahmane M., Vilgrain V., Flejou J.F., and Belghiti J. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg 86 (1999) 176-180
52. Ikeda K., Kumada H., Saitoh S., Arase Y., and Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the Cox proportional hazard model. Cancer 68 (1991) 2150-2154
53. Brown D.B., Fundakowski C.E., Lisker-Melman M., et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 15 (2004) 1209-1218
54. Poon R.T., Ngan H., Lo C.M., Liu C.L., Fan S.T., and Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 73 (2000) 109-114
55. Georgiades C.S., Hong K., D'Angelo M., and Geschwind J.F. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16 (2005) 1653-1659
56. Fan J., Wu Z.Q., Tang Z.Y., et al. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 7 (2001) 28-32
57. Lee H.S., Kim J.S., Choi I.J., Chung J.W., Park J.H., and Kim C.Y. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 79 (1997) 2087-2094
58. Caturelli E., Siena D.A., Fusilli S., et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 215 (2000) 123-128
59. Tarazov P.G., Polysalov V.N., Prozorovskij K.V., Grishchenkova I.V., and Rozengauz E.V. Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 41 (2000) 156-160
60. Kobayashi S., Nakanuma Y., Terada T., and Matsui O. Postmortem survey of bile duct necrosis and biloma in hepatocellular carcinoma after transcatheter arterial chemoembolization therapy: relevance to microvascular damages of peribiliary capillary plexus. Am J Gastroenterol 88 (1993) 1410-1415
61. Yu J.S., Kim K.W., Jeong M.G., Lee D.H., Park M.S., and Yoon S.W. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol 25 (2002) 270-274
62. Kim W., Clark T.W., Baum R.A., and Soulen M.C. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12 (2001) 965-968
63. Song S.Y., Chung J.W., Han J.K., et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12 (2001) 313-320
64. Lopez Jr. R.R., Pan S.H., Hoffman A.L., et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 137 (2002) 653-657
65. Cheung Y.C., Ko S.F., Ng S.H., Chan S.C., and Cheng Y.F. Survival outcome of lobar or segmental transcatheter arterial embolization with ethanol-lipiodol mixture in treating hepatocellular carcinoma. World J Gastroenterol 11 (2005) 2792-2795
66. Huppert P.E., Lauchart W., Duda S.H., et al. Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival?. Rofo 176 (2004) 375-385
67. Chung J.W., Park J.H., Han J.K., Choi B.I., and Han M.C. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 165 (1995) 315-321
68. Allgaier H.P., Deibert P., Olschewski M., et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients. Int J Cancer 79 (1998) 601-605
69. Cady B. Natural history of primary and secondary tumors of the liver. Semin Oncol 10 (1983) 127-134
70. Chen S.C., Hsieh M.Y., Chuang W.L., Wang L.Y., and Chang W.Y. Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 9 (1994) 1-6
71. Giannelli G., Pierri F., Trerotoli P., et al. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival: a retrospective clinical study of 150 cases. Hepatol Res 24 (2002) 50